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Transmissible spongiform encephalopathies are fatal neurodegenerative diseases attributed to misfolding of the cellular prion protein,
PrPC, into a -sheet-rich, aggregated isoform, PrPSc. We previously found that expression of mouse PrP with the two amino acid
substitutions S170N andN174T, which result in high structural order of the2–2 loop in the NMR structure at pH 4.5 and 20°C, caused
transmissible de novo prion disease in transgenicmice. Herewe report that expression ofmouse PrPwith the single-residue substitution
D167S, which also results in a structurally well ordered2–2 loop at 20°C, elicits spontaneous PrP aggregation in vivo. Transgenicmice
expressing PrPD167S developed a progressive encephalopathy characterized by abundant PrP plaque formation, spongiform change, and
gliosis. These results add to the evidence that the2–2 loop has an important role in intermolecular interactions, including that it may
be a key determinant of prion protein aggregation.
Introduction
Prion diseases are infectious and invariably fatal neurodegenera-
tive disorders caused by the conversion of cellular prion protein,
PrPC, into a misfolded and aggregated isoform known as PrPSc
(Prusiner, 1982, 1998; Collinge, 2001; Deleault et al., 2007;Wang
et al., 2010). In humans, prion diseases occur in rare cases spon-
taneously, can be initiated by infection, or are related to inherited
mutations in the prion gene, PRNP, which encodes for 208 resi-
dues in the mature polypeptide chain (Aguzzi and Calella, 2009).
PrPC consists of a flexible, unstructured N-terminal tail and a
globular C-terminal domain comprising three -helices and a
short -sheet, and is highly conserved among mammals (Riek et
al., 1996; Zahn et al., 2000; Gossert et al., 2005; Lysek et al., 2005).
Pathogenic PRNPmutations can affect all regions of the protein
but display some clustering toward the C terminus (Riek et al.,
1998). Particular mutations are destabilizing, such as T183A,
which eliminates two hydrogen bonds linking helix 2 and the
-sheet, yet mutations in the flexibly extended N-terminal
domain do not affect stability (Riek et al., 1998). Certain Prnp
mutants in transgenic mice can reproduce PrP aggregation,
clinical neurologic signs, and PrP plaques in the brain as seen
in the familial diseases (Hsiao et al., 1990; Chiesa et al., 1998;
Dossena et al., 2008; Jackson et al., 2009; Sigurdson et al.,
2009).
NMR spectroscopy has shown that in the solution structure at
20°C, the2–2 loop (aa 166–172) can be either structurally well
ordered (“rigid loop,” RL), or disordered (Riek et al., 1996; Gos-
sert et al., 2005). We previously obtained a well defined 2–2
loop structure by two amino acid exchanges in mouse PrP,
S170N and N174T, and expressed the mutated Prnp gene in
transgenic mice. The resulting RLmice developed a spontaneous
prion disease and also showed altered susceptibility to infection
by prions derived from other species (Sigurdson et al., 2009,
2010). Thus, the 2–2 loop emerges as a critical region in the
PrPC structure that influences prion self-association and cross-
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species infections, yet the underlying molecular mechanism is
incompletely understood.
To further investigate how the loop topology impacts PrP
aggregation in vivo, we have developed a second rigid loop trans-
genic mouse that expresses mouse PrP containing the single-
amino acid residue substitutionD167S. The horsePrnp sequence
normally encodes a serine at position 167, and the NMR struc-
tures of horse PrPC and of mouse PrPC with the D167S sub-
stitution (MoPrP167) both show a structurally well defined
2–2 loop in solution at 20°C (Pe´rez et al., 2010). We now
find that overexpression of MoPrP167 leads to widespread PrP
aggregation in the brain of transgenicmice, similar to that seen in
the previously studied RL mice (MoPrP170,174).
Materials andMethods
Generation of transgenic mice expressing MoPrP167
Single-point mutations (GAT3AGT) that alter the amino acid se-
quence to 167S were created within a pMECA subclone, based on pHG-
PrP (Fischer et al., 1996), using the Stratagene
point mutagenesis kit (primers: forward, 5-
GGCCAGTGAGTCAGTACAGCAACCAG
AAC AAC TTC GTG CAC GAC-3 and re-
verse, 5-GTCGTGCACGAAGTTGTT CTG
GTT GCT GTA CTG ACT CAC TGGCC-3).
The PmeI/NheI pMECA subclone was then
cloned into the PmeI/NheI sites of the pHGPrP
plasmid, and the entire ORF was sequenced
(Rosenberg et al., 1977). The pHGPrP plasmid
containing the mutated Prnp was propagated
inEscherichia coliTop10 cells (Invitrogen), and
the PrP mini-gene sequence was excised with
NotI/SalI. Constructs were microinjected into
the pronucleus of fertilized B6;129S5-Prnp/o
oocytes (Prnp-KO Zurich I) using conven-
tional methods (Ru¨licke, 2004). Founder lines
were identified by PCR for the transgene using
the exon-2 primer pE2 (5-CAA CCG AGC
TGA AGC ATT CTG CCT-3) and the exon-3
primer Mut217 (5-CCT GGG ACT CCT TCT
GGT ACC GGG TGA CGC-3), and founders
were bred to Prnpo/o mice. Six transgene-
carrying founder mice were identified;
Tg(PrnpD167S)77–82Biat. Two lines were main-
tained by crossingwith Prnpo/omice. To identify
the KO neo-cassette, PCR analysis was per-
formed using the primers P10 (Prnp exon 3, 5-
GTACCCATAATCAGTGGAACAAGCCCA
GC-3, 3NC (non-coding region at 3of exon 3,
5-CCCTCCCCCAGCCTAGACCACGA-3),
and P3 (neoR gene, 5-ATT CGC AGC GCA
TCG CCT TCT ATC GCC-3); P10 and 3NC
gave a 560-bp signal for the Prnp allele, and P3
and 3NC gave a 362-bp product for the Prnp
allele. As an alternative test for the presence or
absence of the endogenousPrnp allele, an addi-
tional PCR was performed using the primers P2
(Prnp int2, 5-ATA CTG GGC ACT GAT ACC
TTGTTCCTCAT-3) andP10rev (reverse com-
plementary of P10 5-GCTGGGCTTGTTCCA
CTG ATT ATG GGT AC-3), generating a
352-bp amplicon for the Prnp allele.
Tga20 transgenic mice, which overexpress
murine PrP (Fischer et al., 1996), were used
as controls for many of these experiments.
Male and female mice were used in these
studies and were maintained under specific
pathogen-free conditions. This study was
performed in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory An-
imals of the National Institutes of Health. The study protocol was
approved by the University of California San Diego Institutional An-
imal Care and Use Committee as well as the Zu¨rich Cantonal Veter-
inary Office in Switzerland.
Western blots
Ten percent tissue homogenates were prepared in PBS using a Bead-
beater tissue homogenizer. Extracts of 50–90 g of protein were di-
luted in a Tris HCl-based buffer (10 mM Tris, 10 mM EDTA, 100 mM
NaCl, 0.5% NP40, and 0.5% DOC) and digested with 5–50 g/ml
proteinase K (PK) for 30 min at 37°C. A lithium dodecyl sulfate
(LDS)-based buffer was then added, and the samples were heated to
95°C for 5 min before electrophoresis through a 12% Bis-Tris precast
gel (Invitrogen), followed by transfer to a nitrocellulose membrane by
wet blotting. Proteins were detected with anti-PrP antibody POM1
(epitope in the globular domain, aa 121–230) (Polymenidou et al.,
2008). For secondary detection we used an HRP-conjugated anti-
Figure 1. Tg(MoPrP 167) mice express mouse PrP with a D167S substitution. A, Backbone fold of the2–2 loop (shown are
residues 165–175) in the NMR structures at 20°C of MoPrP 167 (orange; left) andMoPrP (white; right). The drawings are based on
the atomic coordinates of the PDB deposits 2KU5 and 1XYX, respectively, as previously published. The thickness of the spline
function through the C-atoms represents the precision of the structure determination. B, Amino acid sequence comparison of
MoPrP, the previously studiedMoPrP 170,174, and the newly generatedMoPrP 167. Below the sequences is the half-genomicmouse
Prnp gene construct with the enzyme restriction sites and PCR primer sites used for cloning. C, Brain PrP expression levels in
wild-type, Tga20, Prnpo/o, and two lines of Tg(MoPrP 167)mice, denoted Tg81 and Tg82.D, PrP C expression in peripheral organs of
the Tg(MoPrP 167)mouse shows that the highest-expressing organswere heart,muscle and kidney. E, Flotation assay of PrP C after
density gradient centrifugation of brain shows a concurrence of PrP and flotillin inWTand Tg(MoPrP 167)mice, indicating residency
of PrP within detergent-resistant membranes. F, Survival curves of F35 mice expressing amino-proximally truncated MoPrP
(32–134) show rescue of the F35 phenotype through coexpression ofMoPrP (WT) orMoPrP 167. A log-rank test indicated further
that the F35; Prnpo/o and the F35; Tg(MoPrP 167) curves are significantly different. G, Cerebellum from TgF35mice that co-express
either MoPrP 167 (middle) or MoPrP (right) show a rescue of the severe CGC layer degeneration that occurs in the TgF35; Prnpo/o
mice (left). The width of the CGC layer is noted. Scale bar, 250m.
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mouse IgG antibody (Jackson Immunolabs). Signals were visualized
with the ECL detection kit (Pierce).
Flotation assay. Brain homogenates were lysed in cold TNE buffer (25
mM Tris HCl, pH7.5, 150mMNaCl, 5 mM EDTA, and 1%Triton X-100).
Extracts were mixed with two volumes of 60% Optiprep (Nycomed) to
reach a final concentration of 40%. The mixture was carefully overlaid
with a 5 and 30% Optiprep step-gradient and ultracentrifuged at
100,000 g for 20 h at 4°C. Thirteen fractionswere collected andused for
SDS-PAGE and immunoblot analysis using anti-PrP (Pom1) and anti-
flotillin (Abcam) antibodies.
Detection of insoluble PrP
Brain homogenate samples were lysed in a Tris HCl-based buffer (10
mM Tris HCl, pH 8.0, 10 mM EDTA with 2% sarcosyl) and incubated
at 37°C for 1 h before ultracentrifugation at 150,000  g for 1 h.
Supernatant and pellet fractions were collected and treated with a
nuclease (Benzonase). Supernatant proteins were concentrated by
methanol precipitation before Western blotting.
Velocity sedimentation
Brain homogenates were lysed in a Tris HCl-based buffer containing 1%
sarcosyl and incubated at 37°C for 10min before layering over a 10–54%
iodixanol gradient. Dextran blue (2000 kDa) was layered over a separate
gradient as a reference standard. The samples were ultracentrifuged at
200,000 g for 1 h and 175 l fractions were collected and examined by
Western blotting.
PrP peptide ELISA
The peptide ELISA was performed as described by Lau et al. (2007) with
minor modifications. Brain homogenate was mixed with an equal vol-
ume of lysis buffer (100 mM Tris HCl, pH 7.5, 150 mM NaCl) containing
2% sarcosyl, incubated for 10 min at 37°C, and centrifuged at 500 g to
remove cell debris. The supernatant was incubated with peptide-coated
magnetic beads (M-280, Invitrogen) for 1 h at 37°C with constant shak-
ing. The beads were washed with TBS containing 0.1% Tween 20, before
denaturation with 0.1 M NaOH and neutralization with 0.3 M NaH2PO4.
PrPwas thenmeasured by standard sandwich ELISAusing a 96-well plate
precoated with 2.5 g/ml POM-2 antibody, and using a biotinylated
POM-1 antibody (50 ng/ml), followed by streptavidin HRP and an Ultra
TMB-ELISA substrate (Thermo Scientific) for detection. RML-infected
and uninfected control brain samples were included in every experiment.
Samples were run in triplicate.
Immunoprecipitation
15B3 immunoprecipitation. Samples were homogenized in Prionics buf-
fer (Prionics, Switzerland) supplemented with protease inhibitors (1mM
PMSF and Complete TM; Roche). IgM-Dynabeads (Invitrogen) were
used for preclearing the samples for 2 h at 25°C. For the immunopre-
cipitation (IP), the sample was added to 15B3-conjugated IgM Dyna-
beads and shaken at 25°C for 16 h. Beads were washed and bound
sample was eluted with an LDS-based sample buffer.
PrP 136–158 IP. Brain homogenate was lysed in PBS buffer containing
1% Triton X-100 and protease inhibitors, and centrifuged at 500 g for
15min. The supernatantwas incubatedwith 3g of 136–158 antibody in
450 l of lysis buffer and shaken for 2 h at 25°C. A total of 25 l of goat
anti-human (Fab)2-conjugated Dynal beads were added to each tube
followed by a second round of incubation at 25°C for 16 h at 1000 rpm.
The beads were washed in lysis buffer and eluted as described above. The
eluted material was analyzed by SDS-PAGE, and immunoblotting was
performed using the anti-PrP Pom1 antibody.
Histopathology and immunohistochemical stains
Two-m-thick sections were cut onto positively charged silanized glass
slides and stained with hematoxylin and eosin, or immunostained using
antibodies for PrP (SAF84), for astrocytes (GFAP), or microglia (Iba1).
For PrP staining, sections were deparaffinized and incubated for 6min in
98% formic acid. Sections were heated to 100°C in a pressure cooker or
Figure 2. Aged Tg(MoPrP 167) mice develop spontaneous neurologic disease with spongiform encephalopathy and prion plaques in brain. A, Survival curves of a line (L) of transgenic mice (L81)
that expresses high levels of MoPrP 167. B, Aged Tg(MoPrP 167) mice (L81) with clinical neurologic signs including a stiff tail (left, arrow) and kyphosis (middle, arrow) are compared with a healthy
Tga20mouse (right). C, Brain at the level of the frontal cortex has extensive spongiform change (HE), PrP aggregates, and activated astrocytes andmicroglia in Tg(MoPrP 167) mice but not in Tga20
mice. Scale bar, 100m.
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autoclaved in citrate buffer, pH 6.0, and then cooled for 3 min. Im-
munohistochemical stains were performed on an automated Nexus
staining apparatus (Ventana Medical Systems) using an IVIEW DAB
Detection Kit (Ventana). After incubation with protease 1 (Ventana)
for 16 min, sections were incubated with anti-PrP SAF-84 (SPI bio;
1:200) for 32 min. Sections were counterstained with hematoxylin.
GFAP immunohistochemistry for astrocytes (1:1000 for 24 min;
DAKO) and Iba1 (1:2500 for 32 min; Wako Chemicals) for microglia
was similarly performed, however with antigen retrieval by heating to
100°C in EDTA buffer (pH  8.0).
Luminescent conjugated polymer staining of tissue sections
The synthesis of polythiophene acetic acid (PTAA) (mean molecular
weight, MW  3 kDa) has been reported (Ding et al., 2000; Ho et al.,
2002). Frozenmouse brain sections were dried for 1 h and fixed in 100%
ethanol for 10min. After washingwith deionizedwater, the sectionswere
equilibrated in the incubation buffer, consisting of 100 mM sodium car-
bonate at pH  10.2. Luminescent conjugated polymers (LCPs) were
diluted in the sodium carbonate buffer (0.01 g/l), then added to the
brain sections and incubated for 30min at room temperature, and finally
washed with the sodium carbonate buffer.
Fluorescence microscopy
Spectra were collected with a Zeiss Axioplan 2 microscope, fitted with a
Spectraview 4.0 (Applied Spectral Imaging,Migdal, Israel) and a Spectra-
Cube (interferometrical optical head SD 300) module with cooled CCD-
camera, through a 405/30 nm (LP 450) or a 470/40 nm (LP 515) bandpass
filter. The data were processed with SpectraView 3.0 EXPO. Spectra were
collected from 10 individual spots within 3–5
plaques and fromunstained regions andmock-
inoculated negative control Tga20 mice. Fluo-
rescent spectral unmixing was performed
using the function in the software.
Statistical methods
For spectral collection of PTAAbound to prion
aggregates, brain sections were analyzed as fol-
lows: 10 individual spots within each of 3–5
plaques from each case were examined, yield-
ing 30–50 measurements per mouse. The flu-
orescent intensity ratios were calculated
(intensity at 532 nm/emission maximum, and
532/641) and mean and SD were recorded for
each spectral ratio for each individual. An un-
paired, two-tailed Student’s t test was per-
formed using mean values of single animals as
observations. Differences were considered sta-
tistically significant at p 0.05 (2-tailed).
Results
Generation and characterization of
MoPrP167 transgenic mice
We generated 6 founder lines of trans-
genic mice that express mouse PrPwith a
D167S substitution, which imparts a struc-
turallywell ordered2–2 loop in theNMR
solution structure determined at 20°C
(Fig. 1A), similar to that in variant
mouse PrP with S170N and N174T sub-
stitutions (MoPrP170,174, line Tg1020)
(Sigurdson et al., 2009). To do this, we
cloned the transgene into the “half-
genomic” mouse Prnp minigene (pHG-
PrP) containing the prion promoter and
the Prnp open reading frame (Fischer et
al., 1996) (Fig. 1B), and introduced the
construct into Prnp/ zygote pronu-
clei by microinjection. We bred the Tg-
(MoPrP167) founders to B6J;129S5
Prnpo/o mice, and quantified the PrPC expression in brain
from each mouse line by Western blot and ELISA. We chose
two lines, 81 and 82, which express 3- to 5-fold and 1- to
2-fold PrP levels in brain when compared with WT mice, re-
spectively (Fig. 1C). Heart, lung, liver, stomach, spleen, and
kidney were histologically normal. The highest PrP-expressing
tissues in the Tg(MoPrP167) mice were the CNS, skeletal mus-
cle, and heart muscle (Fig. 1D).
MoPrP167 in youngmice is biochemically and functionally
indistinguishable fromWT-PrP in vivo
PrPC from the Tg(MoPrP167) mice was glycosylated and ap-
peared to be processed normally (Fig. 1C). Similar to WT PrP,
MoPrP167 was buoyant in density gradients and colocalized
with flotillin, indicating residency within detergent-resistant
membranes (Fig. 1E). Mutant PrPC functionality was assessed
indirectly by crossing the Tg(MoPrP167) mice with hemizy-
gous TgF35 transgenic mice expressing amino-proximally
truncated PrP(32–134) (Shmerling et al., 1998; Barmada and
Harris, 2005; Radovanovic et al., 2005). TgF35 mice develop
cerebellar granular cell (CGC) degeneration followed by death
at 3–4 months of age, which is rescued by coexpression of
wild-type MoPrP. To assess whether the MoPrP167 would also
rescue the F35 phenotype, we crossed the Tg(MoPrP167) (line
Figure 3. Congo red and PTAA binding properties of de novo MoPrP 167 aggregates. A, PrP aggregates in Tg(MoPrP 167) or
Tg1020 (MoPrP 170,174)mice donot stainwith Congo red.B, PrP aggregates in Tg(MoPrP 167) and Tg1020 (MoPrP 170,174)mice bind
PTAA. C, Emission spectra of PTAA bound to MoPrP 167 and MoPrP 170,174 plaques (left). Correlation diagram of the ratio of light
intensity emitted at 532/emissionmaximum (R532/Emax) and 532/641 (R532/641) from PTAA bound to MoPrP
167 andMoPrP 170,174
plaques compared with mouse-adapted strains of chronic wasting disease (mCWD) or sheep scrapie (mNS) in individual mice
(right). Scale bar, 100m.
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82) and TgF35 mice. Similar to the TgF35 mice that coexpress
wild-type MoPrP, the TgF35 mice that coexpressed MoPrP167
survived beyond 300 d of age (Fig. 1F) (p-value 0.001, log
rank test) and did not develop CGC degeneration (Fig. 1G),
indicating that the MoPrP167 was functioning similarly to
MoPrP.
Aged Tg(MoPrP167) mice develop spontaneous neurologic
disease, spongiform degeneration, and PrPSc deposits in
brain
Aging Tg(MoPrP167) mice from line 81 developed a slowly pro-
gressive neurologic disease characterized by ataxia, tremors,
weight loss, kyphosis, and in some cases priapism, which was
associated with striking degenerative lesions in the brain (Fig.
2A–C). Both diffuse and scattered PrP-immunoreactive plaques
andmoderate neuropil vacuolation occurred in the basal ganglia,
thalamus, and cerebral cortex (Fig. 2C). We detected intense as-
trogliosis and severemicroglial activation in the vacuolated brain
regions (Fig. 2C), as typically seen in transmissible spongiform
encephalopathies.
MoPrP167 aggregates in the brain are labeled by LCPs
The PrP aggregates in the Tg(MoPrP167) mice were not stained
by Congo red (Fig. 3A), yet were stained by PTAA, which we
have previously described as a new tool to distinguish prion
strains (Fig. 3B) (Ding et al., 2000). PTAA molecules interact
with amyloid (Nilsson et al., 2005, 2010) and emit light with a
distinct pattern of spectral intensities depending on the amy-
loid bound (Nilsson et al., 2007; Sigurdson et al., 2007), and
may therefore serve as a surrogate marker of conformation. To
compare the conformation of PTAA bound to de novo
MoPrP167 and MoPrP170,174 aggregates, we measured the
emission spectrum from PTAA labeled brain sections. We
found no differences in the PTAA emission spectra between
the MoPrP167 and MoPrP170,174 PrP aggregates (Fig. 3C), sug-
gesting that aggregates from mice expressing RL-PrP based on
different residue substitutions have a common underlying
structural feature.
Aggregated PrP in the Tg(MoPrP167) mice from line 81 is
insoluble and PK sensitive
To assess whether the sarcosyl-insoluble PrP occurred in brains
of the Tg(MoPrP167) mice, we performed ultracentrifugation on
brain homogenates fromyoung and oldTg(MoPrP167)mice,WT
mice, mice infected with mouse-adapted scrapie (RML strain),
and Tga20mice, which overexpress WT mouse PrP (4- to 6-fold
WT). We found that40% of the PrP was sarcosyl-insoluble in
aged line 81 mice, which was significantly more than in WT
(22%), lower expressing line 82 (13%), and young line 81 (23%)
mice, but less than in mice infected with RML prions (62%)
(Fig. 4A). Also, aged untreated Tga20 mice, 370–500 d old,
spontaneously showed moderate amounts of insoluble PrP
(30%) (Fig. 4A).
Since PrPSc in prion-infected brain is typically PK resistant,
we next measured the extent to which PK-resistant PrP could
be detected in the brain of Tg(MoPrP167) mice. Brain homog-
Figure 4. Detection of aggregated PrP in the brain of Tg(MoPrP 167) mice, line Tg81. A, Soluble (S) and insoluble (P) PrP from brain homogenate were separated by ultracentrifugation and
immunoblotting. Percentage of PrP in the pellet fractions was quantified and graphed, with each point representing an individual mouse. Samples labeled L81 yo were from 40-d-old mice, where
as all other uninoculated mice were older than 300 d. B, PK digest of WT and Tg(MoPrP) 167 brain homogenate using a gradient of PK concentrations at 37°C for 30 min reveals that the modified
moPrP 167 is sensitive to PK at	10g/ml PK. C, IP of PrP aggregates using a peptide-grafted antibody, 136–158, reveals abundant PrP Sc in the immunoprecipitated fractions of RML-infected and
line Tg81 (L81)mice, but notWTmice.D, Soluble and insoluble fractionswere each divided for direct immunoblotting or for IP using PrP Sc-specific antibody 15B3 followedby immunoblotting using
anti-PrP antibody POM1. Quantification of the percentage of pellet to total PrP Sc shows that PrP Sc is enriched in the pellet fractions after 15B3 IP (bottom), indicating that the PrP Sc is primarily
insoluble. E, PrP Sc-peptide ELISA of Tg81mice of various ages was positive in all Tg81, Tga20 and scrapie-infectedmice, and negative in Tg82mice. Prnpo/o andWTmice were used to set the upper
threshold for the negative samples.
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enate samples from Tg(MoPrP167) and WT mice were incu-
bated with increasing concentrations of PK. The PrP in the
brain of agedTg(MoPrP167)micewas primarily PK sensitive (Fig.
4B), as often seen in mice expressing mutant PrP (Hsiao et al.,
1990; Jackson et al., 2009; Sigurdson et al., 2009) and in hu-
mans with certain sporadic and familial prion diseases, including
fatal familial insomnia andGerstmann-Stra¨ussler-Scheinker disease
(Medori et al., 1992; Colucci et al., 2006; Gambetti et al., 2008).
We next determined whether the aggregates were captured by
PrPSc-specific antibodies, which may indicate conformational
similarities with infectious PrPSc. We performed immunopre-
cipitation using the PrP peptide 136–158 grafted to an antibody
scaffold that has been shown to bind PrPSc (Moroncini et al.,
2004). Antibody 136–158 immunoprecipitated abundant PrPSc
in brain from RML-infected and Tg(MoPrP167) mice, but not
from WT mice (Fig. 4C). To determine whether the Tg(Mo-
PrP167) PrPSc was soluble or insoluble, we performed ultracentrifu-
gation and immunoprecipitated PrPSc from the supernatant and
pellet fractions using the PrPSc-specific antibody 15B3 (Korth et al.,
1997) (conformational epitope formedbyPrPaa142–148, 162–170,
and 214–226). Here we found that the PrPSc detected in the line 81
mice was primarily in the insoluble fraction, similar to RML scrapie
(Fig. 4D, bottom).
To further detect and quantify PrPSc aggregates, we assessed
whether a PrPSc-specific peptide (aa 23–30) binds MoPrP167 ag-
gregates in a prion assay that excludes PK or other enzyme treat-
ment (Lau et al., 2007). We precipitated the PrPSc aggregates
using PrP peptide bound to magnetic beads, then denatured the
bound aggregates and detected PrP by antibody ELISA.We could
detect PrP aggregates in all 13 of the line 81 and scrapie-infected
mice, but in none of the WT, line 82, or
Prnpo/o mice. Interestingly, aggregates
were also detected in the brains of all aged
Tga20 mice (Fig. 4E), yet signals were sig-
nificantly lower than in the line 81 mice
exceeding 180 d of age (line Tg81 average
0.77, range 0.25–1.3; Tga20: average 0.38,
range 0.20–0.60; p  0.04, Student’s t
test).
PK-sensitive PrPSc has been shown
to correspond to lower density fractions
after density gradient centrifugation
(Pastrana et al., 2006). To determine
whether the aggregates from the
Tg(MoPrP167) mice were also in the
lower density fractions, we measured
the sedimentation properties of PrP
from Tg(MoPrP167), uninfected WT,
Tga20 and RML-infected mice in a 10–
54% iodixanol gradient. WT PrPC was
present primarily in the low density
fractions 1 and 2, whereas RML was pri-
marily in fraction 7. By comparison, the
aged Tg(MoPrP167) showed abundant
PrP in low density fraction 4 (27%), but
with a very small amount (0.5%) de-
tected in the most dense fractions 10
and 11, which was also seen with RML.
These findings indicated that most Mo-
PrP167 aggregates were smaller and more
buoyant thanRML, yet a rare dense aggre-
gate population existed in common with
RML (Fig. 5).
Discussion
Here we show that a single-residue substitution in the 2–2
loop leads to neurodegeneration and prion plaque formation,
as seen in humans with various PRNP mutations (Masters et
al., 1981). The Tg(MoPrP167) and the previously described
Tg(MoPrP170,174) mice are based on rationally designed mod-
ifications of mouse PrP that mimic the well defined 2–2
loop in the NMR structures at 20°C of the elk and horse prion
proteins (Gossert et al., 2005; Pe´rez et al., 2010). We have
previously found that the mutations in the 2–2 loop of
Tg(MoPrP170,174) led to de novo generation of PrP plaques,
spongiform degeneration, gliosis, and infectious prions in vivo
(Sigurdson et al., 2009). Here we showed that except for its PK
sensitivity, the PrPSc in the Tg(MoPrP167) mice has biochem-
ical properties in common with mouse scrapie PrPSc, includ-
ing insolubility, recognition by conformational PrPSc-specific
antibodies and peptides, and binding by PTAA.
Several of the familial prion diseases in humans and related
mouse models also develop PrPSc with biochemical properties
common to our Tg(moPrP167) mice, such as PK sensitivity
and insolubility (Hsiao et al., 1990; Medori et al., 1992; Co-
lucci et al., 2006; Gambetti et al., 2008; Jackson et al., 2009;
Sigurdson et al., 2009). Together, these data suggest that ag-
gregates precipitated by a Prnpmutation might form different
multimeric structures than those acquired by infection. In
support of this hypothesis, we found that PrP aggregates from
our Tg(MoPrP167) mice were found primarily in lower density
fractions than RML mouse PrPSc, indicating that the aggre-
gates may be smaller or have a different shape. Our observa-
Figure 5. Sedimentation properties of the MoPrP 167, RML PrP Sc, WT PrP C, and Tga20 PrP C from brain homogenates. The
MoPrP 167 migrated into fractions 4 and 5, which are more dense than WT PrP C, but less dense than RML-containing fractions.
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tions are consistent with previous work showing PK-sensitive
PrP in lower density fractions (Pastrana et al., 2006). It will be
interesting to determine in future studies the specific aggre-
gate size and whether this low sedimentation property occurs
with additional PK-sensitive prion strains in animals and
humans.
In conclusion, we now have two lines of transgenic mice
expressing MoPrP with different 2–2 loop substitutions
that confer RL-loop characteristics to the NMR structures at
20°C, which both develop PrP aggregates and spongiform de-
generation (Sigurdson et al., 2009). The S170N, N174T sub-
stitutions also had a major impact on species barriers
(Sigurdson et al., 2010). Whether the increased aggregation
tendency and altered species barriers are due to the altered
spatial loop secondary structure, the primary sequence, or a
combination of both is not yet clear. Future studies of the
2–2 loop substitutions should provide insights into the rel-
ative contribution of primary versus secondary structure of
the PrPC substrate in prion assembly. The implicated key role
of the 2–2 loop region in aggregation and species barriers
may thus provide a starting platform for novel approaches to
unravel details of the roles of wild-type prion proteins in
health and disease, with possible leads into the rational design
of therapies to block PrP aggregation.
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